Cargando…

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

BACKGROUND: Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis. METHOD: We examined whether weekly DPP4 inhibitor omarigli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattori, Sachiko, Nomoto, Kazuomi, Suzuki, Tomohiko, Hayashi, Seishu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945344/ https://www.ncbi.nlm.nih.gov/pubmed/33691757 http://dx.doi.org/10.1186/s13098-021-00644-5

Ejemplares similares

An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2016)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Ahsan, Farah, et al.
Publicado: (2020)

Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver
por: Li, Chao, et al.
Publicado: (2020)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
por: Kim, Jeong Woo, et al.
Publicado: (2020)

Identification of Autophagy-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis
por: Ma, Mengyao, et al.
Publicado: (2021)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology
por: Akter, Sharmin
Publicado: (2022)

Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review
por: Eguchi, Yuichiro, et al.
Publicado: (2020)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli, Surosree, et al.
Publicado: (2019)

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review
por: Yaqub, Sayma, et al.
Publicado: (2021)

Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Holzner, Lorenz M. W., et al.
Publicado: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus, Johanne Sloth, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
por: Hattori, Sachiko
Publicado: (2020)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Recent advances in non-alcoholic fatty liver disease
por: Polewiczowska, Beata, et al.
Publicado: (2018)

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
por: Safaei, Akram, et al.
Publicado: (2016)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
por: Nachit, Maxime, et al.
Publicado: (2020)

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
por: Di Pasqua, Laura Giuseppina, et al.
Publicado: (2022)

The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients
por: Kenger, Emre Batuhan, et al.
Publicado: (2020)

Transcriptional and Epigenetic Alterations in the Progression of Non-Alcoholic Fatty Liver Disease and Biomarkers Helping to Diagnose Non-Alcoholic Steatohepatitis
por: Zhu, Yalan, et al.
Publicado: (2023)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis
por: Atanasovska, Biljana, et al.
Publicado: (2021)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

A New Rodent Model of Non-Alcoholic Steatohepatitis and Metabolic Syndrome
por: Romeiro, Fernando Gomes, et al.
Publicado: (2019)

S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis
por: Liu, Xiaolin, et al.
Publicado: (2015)

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)

Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
por: Saenz, Marissa, et al.
Publicado: (2023)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Dementia and non-alcoholic fatty liver disease – An unprecedented relationship
por: Latif, Fakhar, et al.
Publicado: (2022)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
por: Marmur, Joel, et al.
Publicado: (2018)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Fatty Acid Elongation in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Kessler, Sonja M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h8sve93g2r2a07hsn10boh85j4